Clinical Trial

Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the safety and tolerability of intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-05.
Trial Details
NCT Number NCT07454031
Lead Sponsor Peking University
Collaborators: Shenzhen Bay Laboratory
Conditions Peritoneal (Metastatic) Cancer
Enrollment 22 participants
Start Date 2026-03-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13